RESUMO
Statement of Problem: Ameloblastomas are locally aggressive tumors with which the researchers have been mostly concerned to understand their biological behavior. Overexpression of minichromosome maintenance 3 [MCM3, a recently introduced marker] has been reported in different cancers. There is no study about MCM3 expression in ameloblastoma
Purpose: This study aims at the evaluation of MCM3, Ki-67 and p27 in ameloblastoma
Methods and Material: In this analytical study, 18 ameloblastomas were selected. Clinicohistopathological data were recorded and immuohistochemical staining was done on the newly cut sections for Ki-67 antigen, p27 kip1 and MCM3. The immunostained cells were counted on 10 HPF [Labeling Index] and then classified into negative [LI50] levels. Statistical analysis was performed in SPSS, version 13, using ordinal regression and Freidman tests. P value less than 0.05 was considered significant
Results: Among the lesions, 5 [27.8%] and 13 [72.2%] were negative and weak for Ki-67, respectively. Also, 5 [27.8%], 11[61.1%] and 2 [11.1%] lesions were negative, weak and moderate, respectively for p27. Ki-67 and p27 staining were seen more frequently in the ameloblast layer and stellate reticulum, respectively. None of the samples was stained by MCM3. There were significant differences among Ki-67, p27 and MCM3 expression in ameloblastomas but no differences were found between sex, age and tumor size and expression of these markers
Conclusion: Most of the ameloblastomas expressed low levels of Ki-67 and p27 [72.2% and 61.1%, respectively]. It could not be concluded exactly how these tumors will behave in the future, because low expression of p27 is in favor of cell proliferation [in contrast to low expression of Ki-67]. To find out how biological behavior of these tumors will be in the future, other markers should be evaluated and all the patients should be followed up. Regarding the negative expression of MCM3 in all lesions, it seems that MCM3 is not involved in the pathogenesis of ameloblastoma
RESUMO
Metastatic tumors in the oral cavity account for about 1% of oral malignant tumors. They are mostly located in the mandible, predominantly in the molar region. All dentists and specialists must recognize oral metastatic lesions because they can be the first sign of an undiscovered malignancy, and also they can be easily mistaken with several different benign lesions. The aim of this study is to introduce a patient with metastatic follicular carcinoma of thyroid gland in the palate. A 71 years old female was referred to a private office with chief complaint of halitosis. A tumoral mass was found in the hard palate on clinical examination. Destruction of floor of maxillary sinus and nasal fossa, destruction of lateral wall of nasal fossa and tumor bulging in soft tissue of palate were seen on the CT scan. After seeing the pathology slides and conversation with the patient, previous medical history of thyroid surgery in The UK about 12 years ago was found. Folow up of patient revealed, she died 4months later by extensive lung metastasis